Genitourinary Cancers | Special Reports

Patient-Centered Management of Metastatic Renal Cell Carcinoma

December 05, 2013

Clinical Articles

The development of drugs that target angiogenesis and signal transduction pathways in the treatment of metastatic renal cell carcinoma (RCC) has led to improved survival rates for patients.

Treatment of Advanced Renal Cell Carcinoma

October 26, 2013

Clinical Articles

The treatment of advanced renal cell carcinoma (RCC) remains a major challenge for clinicians. However, according Daniel J. George, MD, the progress being made in understanding RCC tumor biology is already helping us to discover better, more effective treatments.

Treatment Pathways and Sequencing Strategies in CRPC

October 26, 2013

Clinical Articles

An interview with James Mohler, MD, associate director and senior vice president for Translational Research at Roswell Park Cancer Institute, Buffalo, NY, and chair of the NCCN Guidelines Panel for Prostate Cancer.

Therapeutic Strategies for Managing Bone Health in Prostate Cancer

October 26, 2013

Clinical Articles

Over the past three years, diverse new therapies have been approved to treat advanced prostate cancer, including agents that have shown some promise in delaying its progression to the bone.

Factors in Choosing First-Line Targeted Therapy in RCC

October 26, 2013

Clinical Articles

Targeted Oncology spoke with Shilpa Gupta, MD, from the Moffitt Cancer Center and University of South Florida Morisani College of Medicine, on considerations in choice of therapy for first-line treatment of mRCC.

Immune Response in Patients with RCC

October 25, 2013

Clinical Articles

Jeffrey A. Sosman, MD, professor of medicine, director, Melanoma and Tumor Immunotherapy Program, Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, discusses immune response in renal cell carcinoma.

Sequencing Agents to Treat Castration-Resistant Prostate Cancer

October 25, 2013

Clinical Articles

Leonard G. Gomella, MD, FACS, Department of Urology, Thomas Jefferson University, Associate Director, Clinical Affairs, Kimmel Cancer Center, comments on sequencing agents to treat castration-resistant prostate cancer.